The Wockhardt Group, once a prominent player in the pharmaceutical industry, is facing monumental distress. With mounting debts and a struggling business, the group's valuable assets are now being put up for grabs. This dramatic turn of events has sent shockwaves through the industry, spurring speculation within financial circles. It remains to be